Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
Số trang: 9
Loại file: pdf
Dung lượng: 1.05 MB
Lượt xem: 17
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The objective of this study is to evaluate the cost-effectiveness of adding pembrolizumab to the standard first-line therapy of advanced biliary tract cancer (BTC) with gemcitabine and cisplatin from the perspective of the Chinese healthcare system.
Nội dung trích xuất từ tài liệu:
Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
Nội dung trích xuất từ tài liệu:
Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Cost-effectiveness analysis Biliary tract cancers Partitioned survival model Chinese healthcare systemTài liệu liên quan:
-
52 trang 240 0 0
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 175 0 0 -
6 trang 169 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 147 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 125 0 0 -
12 trang 98 0 0
-
19 trang 76 0 0
-
17 trang 68 0 0
-
9 trang 46 0 0
-
12 trang 40 0 0